Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements (vol 5, e225996, 2022)

被引：0
|
作者：
不详
机构：
来源：
JAMA NETWORK OPEN | 2023年 / 6卷 / 07期
关键词：
D O I：
10.1001/jamanetworkopen.2023.27991
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页数：1
相关论文
共 13 条
  • [1] Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements
    Spetz, Joanne
    Hailer, Laurie
    Gay, Caryl
    Tierney, Matthew
    Schmidt, Laura
    Phoenix, Bethany
    Chapman, Susan
    JAMA NETWORK OPEN, 2022, 5 (05)
  • [2] Evaluating Changes in Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder Before and During the COVID-19 Pandemic
    Nguyen, Anh
    Binswanger, Ingrid
    Narwaney, Komal
    Xu, Stanley
    McClure, David
    Rinehart, Deborah
    Glanz, Jason
    DRUG AND ALCOHOL DEPENDENCE, 2024, 260
  • [3] USE OF BUPRENORPHINE FOR OPIOID USE DISORDER AMONG US ADOLESCENTS AND YOUNG ADULTS DURING THE COVID-19 PANDEMIC
    Alinsky, Rachel
    Prichett, Laura
    Chang, Hsien-Yen
    Alexander, G. Caleb
    Stein, Bradley
    Saloner, Brendan
    JOURNAL OF ADOLESCENT HEALTH, 2022, 70 (04) : S16 - S16
  • [4] Changes in transmucosal buprenorphine utilization for opioid use disorder treatment during the COVID-19 pandemic in Kentucky
    Lei, Feitong
    Lofwall, Michelle R.
    Freeman, Patricia R.
    Slade, Emily
    Vickers-Smith, Rachel
    Slavova, Svetla
    JOURNAL OF RURAL HEALTH, 2023, 39 (01): : 186 - 196
  • [5] Treatment of Opioid Use Disorder With Buprenorphine Among US Adolescents and Young Adults During the Early COVID-19 Pandemic
    Alinsky, Rachel H.
    Prichett, Laura
    Chang, Hsien-Yen
    Alexander, G. Caleb
    Stein, Bradley D.
    Saloner, Brendan
    JOURNAL OF ADOLESCENT HEALTH, 2022, 71 (02) : 239 - 241
  • [6] Characteristics and correlates of US clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic
    Jones, Christopher M.
    Diallo, Mamadou M.
    Vythilingam, Meena
    Schier, Joshua G.
    Eisenstat, Matthew
    Compton, Wilson M.
    DRUG AND ALCOHOL DEPENDENCE, 2021, 225
  • [7] Use of Telehealth Across Pediatric Subspecialties Before and During the COVID-19 Pandemic (vol 5, e224759, 2022)
    Uscher-Pines, L.
    McCullough, C.
    Dworsky, M. S.
    JAMA NETWORK OPEN, 2022, 5 (04)
  • [8] Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic (vol 5, e2214765, 2022)
    Nguyen, T.
    Ziedan, E.
    Simon, K.
    JAMA NETWORK OPEN, 2022, 5 (07)
  • [9] Assessment of State and Federal Health Policies for Opioid Use Disorder Treatment During the COVID-19 Pandemic and Beyond (vol 2, e213833, 2021)
    Pessar, S. C.
    Boustead, A.
    Ge, Y.
    JAMA HEALTH FORUM, 2022, 3 (01):
  • [10] RETRACTION: Internet of things in the management of chronic diseases during the COVID-19 pandemic: A systematic review (Retraction of Vol 5, art no E557, 2022)
    Shamsabadi, A.
    Pashaei, Z.
    Karimi, A.
    HEALTH SCIENCE REPORTS, 2023, 6 (07)
12